CABIO unveils NeoHMOs™ series at FIE 2023, targeting growing global demand for infant formula

As a core supplier in the global infant formula supply chain, CABIO is committed to upholding its heartwarming corporate philosophy that "behind every can of formula lies a baby", a value that has been cherished from the very beginning of our journey. We consistently maintain world-class standards in food safety and supply chain management, enabling us to provide high-quality functional nutritional products and diversified solutions to our customers in China and beyond. As a core supplier in...

As a core supplier in the global infant formula supply chain, CABIO is committed to upholding its heartwarming corporate philosophy that "behind every can of formula lies a baby", a value that has been cherished from the very beginning of our journey. We consistently maintain world-class standards in food safety and supply chain management, enabling us to provide high-quality functional nutritional products and diversified solutions to our customers in China and beyond.

At the FIE 2023, CABIO unveiled a wide range of products -- arachidonic acid (ARA), docosahexaenoic acid (DHA), sialic acid (SA), β-Carotene, etc. as well as the NeoHMOs™ family, including 2'-Fucosyllactose (2'-FL), 3-Fucosyllactose (3'-FL), lacto-N-tetraose (LNT), lacto-N-neo-tetraose (LNnT), 3'-sialic lactose (3'-SL), and 6'-sialic lactose (6'-SL).

With an unwavering commitment to the brand philosophy that "biotechnology nourishes life", CABIO strives to deliver premium products and innovative solutions to customers in the fields of human nutrition, animal nutrition, cosmetics, and personal care. Our vision is to become a global leader in biotechnology, empowering and enriching lives through nutrition and health.

About Us

Established in September 2004, CABIO Biotech (Wuhan) Co., Ltd. ("CABIO" for short) (SSES: 688089) is a high-tech company founded on biotechnology.

Since initial public offering, CABIO has actively embraced the field of synthetic biology, having established dedicated laboratories and initiated an array of forward-thinking and market-driven research projects. With our synthetic biology platform as the foundation, we have proactively expanded our product portfolio and industry presence, driving the development of new products and fostering the growth of our business. Our commitment lies in leveraging biotechnology to empower life nutrition and health.

www.cabio.com 

Photo - https://mma.prnewswire.com/media/2289167/CABIO_Team_at_FiE.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cabio-unveils-neohmos-series-at-fie-2023-targeting-growing-global-demand-for-infant-formula-302001443.html